Home » 2019 » January
Prana Biotechnology secures orphan designation for PBT434 in MSA

Prana Biotechnology secures orphan designation for PBT434 in MSA

Australian biotech company Prana Biotechnology has secured Orphan Drug designation for PBT434, its lead molecule, for the treatment of Multiple System Atrophy (MSA). Prana Biotechnology claims that its application was based on the proposed use of the molecule as a treatment for MSA, including the medical and scientific rationale. The Australian biotech company said that […]

AgeneBio enrolls first patient in AGB101 phase 3 trial in MCI due to AD

AgeneBio, a US-based CNS biopharma company, enrolled the first patient in a phase 3 clinical trial to study the efficacy of AGB101 for the treatment of amnestic Mild Cognitive Impairment caused by Alzheimer’s Disease (MCI due to AD). The late-stage trial, known as HOPE4MCI, will enroll a total of 830 patients, aged between 55 and […]

Continue reading …
Everything you need to know about warning signs of stomach cancer

It is good to know about the warning signs of stomach cancer as the stomach cancer may go undetected for years. Stomach cancer is also known as gastric cancer and it affects the lining of the stomach before it spreads to other regions of the body. Changes in the stomach lining occur when it is […]

Continue reading …
An egg a day might reduce risk of heart disease: Study

New Delhi, Jan 28 (ANI): A new study conducted in China finds that eating an egg a day may lower risk of cardiovascular disease. The study found that daily egg eaters had an 18 per cent lower risk of dying from cardiovascular disease, reported CNN. Earlier doctors would warn patients against eating too many eggs, […]

Continue reading …
Spectrum offloads seven hematology/oncology drugs to Acrotech in $300m deal

US biopharma company Spectrum Pharmaceuticals has agreed to offload seven of its FDA-approved hematology/oncology drugs to Acrotech Biopharma, a subsidiary of Aurobindo Pharma USA, in a deal worth around $300 million. The decision to sell the drugs has been taken to focus on new and innovative therapies for cancer patients, said Spectrum Pharmaceuticals. The seven […]

Continue reading …
Heavy work pressure may be the reason for gaining weight

New Delhi, Jan 27 (ANI): According to a recent study, work pressures inclined women to weight gain. During the study, researchers saw that high job demands played a part in women’s weight gain while for men there was no association between high demands and weight gain. The results of the study showed that respondents with […]

Continue reading …
FDA accepts X-Rx new drug application for IPD drug X-165

US biotech company X-Rx said that the US Food and Drug Administration (FDA) has accepted its investigational new drug application (IND) for X-165, a small molecule inhibitor of Autotaxin X-165, which is being developed as a new drug for Idiopathic Pulmonary Fibrosis. According to X-Rx, X-165 as an orally delivered agent, has shown promising results […]

Continue reading …
Tamr joins Accenture’s life sciences ecosystem to help drive innovation in drug discovery and scientific research

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Tamr Inc. today announced it has joined Accenture’s open partner ecosystem, designed to help independent software vendors (ISVs) and life science companies team more effectively to accelerate drug discovery efforts and improve patient outcomes. The ecosystem is an integral part of Accenture’s cloud-based informatics research platform, which has been designed to help life sciences organizations […]

Continue reading …
Clovis PARP inhibitor Rubraca gets EC approval for relapsed ovarian cancer

Rubraca EC approval : US biotech company Clovis Oncology has secured approval for an additional indication for its cancer drug Rubraca (rucaparib) in Europe – as maintenance treatment for adult women whose ovarian cancer has relapsed. The approval from the European Commission (EC) is for the PARP inhibitor to be used as monotherapy for patients […]

Continue reading …
Eusa Pharma acquires iMCD drug Sylvant global rights from Janssen

Eusa Pharma has completed acquisition of the global rights of idiopathic multicentric Castleman’s disease drug (iMCD drug) Sylvant (siltuximab) from Janssen Sciences Ireland in an all-cash deal worth $115 million. The deal was signed in July 2018 by Eusa Pharma in a move to significantly consolidate its footprint as a global biopharma company in oncology […]

Continue reading …
Page 1 of 212